Alnylam Pharmaceuticals & Medison Pharma partnership to commercialise RNAi therapeutics in Israel.
Global Banking News-January 21, 2019-Alnylam Pharmaceuticals & Medison Pharma partnership to commercialise RNAi therapeutics in Israel
(C)2019 ENPublishing - http://www.enpublishing.co.uk
RNAi therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Monday announced an exclusive agreement in Israel to commercialise ONPATTRO as well as other investigational therapeutics under its RNAi portfolio through Medison Pharma, Israel's leading commercial partner for innovative pharmaceuticals.
This partnership covers ONPATTRO, approved in the EU in August 2018 for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; givosiran, a late-stage investigational RNAi therapeutic for the treatment of acute hepatic porphyria (AHP); as well as lumasiran, a late-stage investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1 (PH1).
ONPATTRO is currently not approved for use in Israel and givosiran and lumasiran have not yet been approved by any regulatory authority.
RNAi (RNA interference) is reportedly a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognised with the award of the 2006 Nobel Prize for Physiology or Medicine.
((Distributed via M2 Communications - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||Global Banking News (GBN)|
|Date:||Jan 21, 2019|
|Previous Article:||DFDS to restate 2018 financial details on leases according to IFRS.|
|Next Article:||Logitech announces 10 GOOD DESIGN Awards.|